INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action Lawsuit Filed Against Walgreens Boots Alliance, Inc. (NASDAQ: WBA); Investors with Losses Encouraged to Discuss Their Options with Counsel

Class Action Lawsuit Overview - A class action lawsuit has been filed against Walgreens Boots Alliance Inc (WBA) on behalf of purchasers of its common stock between July 1 2021 and June 26 2024 [1] - Investors have until November 18 2024 to seek appointment as lead plaintiff in the lawsuit [1] Walgreens Business Operations - Walgreens operates in three business segments: US Retail Pharmacy International and US Healthcare [3] - In 2019 Walgreens announced a collaboration with VillageMD involving a $1 billion investment and expansion of primary care facilities next to Walgreens stores [3] Lawsuit Allegations - Walgreens allegedly inefficiently deployed capital meant to grow its US Healthcare segment and failed to properly implement its partnership with VillageMD [4] - The company was unable to profitably scale VillageMD and its rollout of clinics did not proceed as planned [4] - Walgreens built too many VillageMD clinics leading to understaffing and fewer patients which slowed the growth of its US Healthcare segment [4] - Executives failed to manage investor expectations about the negative impact of the VillageMD rollout on short-term profits and exaggerated VillageMD's value [4] Financial Performance and Stock Price Impact - On June 27 2023 Walgreens announced disappointing earnings for fiscal Q3 2023 reduced 2023 guidance and revealed slower profit ramp for US Healthcare due to VillageMD's underperformance causing a$2 95 (9 3%) drop in stock price [5] - On July 27 2023 the departure of the CFO caused a $0 83 (nearly 3$1 88 (7 4%) drop in stock price [5] - On January 4 2024 disappointing fiscal Q1 2024 results attributed to VillageMD operations caused a $1 31 (5$3 47 (22%) drop in stock price [6] Legal Representation - DiCello Levitt is handling the class action lawsuit and has achieved top recognition as Plaintiffs Firm of the Year and Trial Innovation Firm of the Year [7][8]